M&A AT A GLANCE

Key Takeaways

- ► U.S. M&A decreased 6% by deal count and 12% by total deal value in September. Globally, deal count decreased 5%, and total deal value decreased 4%. Nevertheless, September still saw the second highest number of deals in the U.S. over the last 12 months (LTM).
- U.S. cross-border activity was mixed, with U.S. outbound activity falling by 14% by deal count but increasing by 12% by deal value. U.S. inbound deals increased by 2%, while total deal value dropped by 34%.
- Computers & Electronics was again the most active industry in September and LTM. Healthcare was the second most active industry in September by deal value, with a significant 126% increase, primarily driven by Baxter International Inc.'s acquisition of Hill-Rom Holdings, Inc. for approximately \$10 billion.
- ➤ SPAC acquisitions decreased significantly in the U.S. for the second month in a row, with a 74% decrease in total deal value and a 62% decrease in deal count in September. Globally, total SPAC deal value increased 54% despite a decrease of 36% in the number of deals.
- U.S. public merger highlights in September include the following:
 - Cash only transactions were up significantly compared to the LTM average at 78% of all U.S. deals, and there were no mixed Cash & Stock or Cash Election deals, which averaged a combined 17% of deals LTM.
 - There were no unsolicited or hostile offers in September, compared to an average of 19% LTM.
 - There were no go-shop provisions in September compared to 8% LTM. Particularly notable was the lack of go-shop provisions in deals with Financial Buyers, which average 30% LTM.

Strategic vs. Sponsor Activity

U.S. Total \$178.9 billion - ▼11.5% 944 deals - ▼6.2% Strategic \$134.0 billion - ▼3.5% 735 deals - ▼4.5% Sponsor \$44.9 billion - ▼29.2% 209 deals - ▼11.4%

Global Total \$484.2 billion - ▼3.9% 2,630 deals - ▼4.4% Strategic \$372.7 billion - ▼2.3% 2,237 deals - ▼3.3% Sponsor

\$111.4 billion - ▼8.9%

393 deals - ▼10.3%

Crossborder Activity

U.S. Inbound U.S. Outbound \$40.8 billion \$86.4 billion **▼34.4% ▲11.7** % 133 deals 113 deals **▲1.5% ▼14.4%** leading country leading country **Germany** – \$11.0 billion **U.K.** – \$27.0 billion Canada – 33 deals Canada – 21 deals leading country leading country last 12 months last 12 months Canada - \$87.5 billion **U.K.** – \$188.9 billion Canada – 299 deals **U.K.** – 329 deals

Industry Activity










SPAC Acquisitions








All data is for September 2021 and is as of October 11, 2021 unless otherwise specified. Each metric in this publication that references deal volume by dollar value is calculated from the subset of the total number of deals that includes a disclosed deal value.

Most Active U.S. Target Industries¹










Average Break Fees as % of Equity Value²



Average Break Fees as % of Equity Value^{3,4}


| | September 2021 Last 12 Months |
|----------------------------------|-------------------------------|
| Target Break Fee for All Mergers | 3.6 3.6 |
| | |
| | September 2021 Last 12 Months |
| | |

| | September 2021 | Last 12 Months |
|--|----------------|----------------|
| Reverse Break Fee for All Mergers⁵ | 5.9 | 5.6 |
| Reverse Break Fee for Mergers Involving Financial Buyers ⁶ | 6.2 | 6.5 |
| Reverse Break Fee for Mergers Involving Strategic Buyers ⁷ | 5.8 | 5.0 |

U.S. Public Merger Go-Shop Provisions⁴

| | September 2021 | Last 12 Months |
|---|----------------|----------------|
| % of Mergers with Go-Shops | 0.0 | 8.1 |
| % of Mergers Involving Financial Buyers with Go- Shops ⁸ | 0.0 | 29.5 |
| % of Mergers Involving Strategic Buyers with Go- Shops ⁹ | 0.0 | 0.8 |
| Avg. Go-Shop Window (in Days) for All Mergers with Go-Shops ¹⁰ | N/A | 36.1 |
| Avg. Go-Shop Window (in Days) for Mergers Involving Financial Buyers with Go-Shops ¹¹ | N/A | 35.8 |
| Avg. Go-Shop Window (in Days) for Mergers Involving Strategic Buyers with Go-Shops ¹² | N/A | 41.0 |

Form of Consideration as % of U.S. Public Mergers¹³



Tender Offers as % of U.S. Public Mergers

| September 2021 | 11.1 |
|----------------|------|
| Last 12 Months | 13.4 |

Hostile/Unsolicited Offers as % of U.S. Public Mergers¹⁴

| September 2021 | 0.0 |
|----------------|------|
| Last 12 Months | 18.9 |


Unaffected Premium %14,15

| September 2021 | 32.7 |
|----------------|------|
| Last 12 Months | 36.7 |


Total Target Adviser Fee(s) as % of Equity Value


| September 2021 | 1.3 |
|----------------|-----|
| Last 12 Months | 1.2 |

Top 5 Countries of Origin for Inbound U.S. Crossborder Transactions




Top 5 Countries of Destination for Outbound U.S. Crossborder Transactions






Appendix: M&A Activity – 12 Month Trends




Global Deal Value (US\$B)








Global Number of Deals










Outbound U.S. Crossborder Transactions







Global Crossborder Transactions



Endnotes

- 1. Industries categories are determined and named by Cortex.
- 2. Based on the highest target break fees and reverse break fees payable in a particular deal.
- 3. There were nine transactions in September 2021.
- 4. Financial and strategic categories are determined by Deal Point Data.
- Six transactions in September 2021 had a reverse break fee.
- 6. One transaction in September 2021 involving a financial buyer had a reverse break fee.
- 7. Five transactions in September 2021 involving a strategic buyer had a reverse break fee.
- 8. One transaction in September 2021 involved a financial buyer.
- 9. Eight transactions in September 2021 involved a strategic buyer.
- 10. Zero transactions in September 2021 had a go-shop provision.
- 11. Zero transactions in September 2021 involving a financial buyer had a go-shop provision.
- 12. Zero transactions in September 2021 involving a strategic buyer had a go-shop provision.

- 13. Due to rounding, percentages may not add up to 100%.
- 14. This data includes both announced transactions for which a definitive merger agreement was reached and filed and those for which a definitive merger agreement was never reached and filed (including withdrawn transactions).
- 15. Unaffected Premium % indicates the difference between the current price per share offered as consideration in the transaction and the "unaffected price", reflected as a percentage. The "unaffected price" is the target's closing stock price on the date that is one calendar day prior to the first public disclosure regarding a potential deal involving the target and on which the target's stock price was unaffected by the news of the deal.
- Each of Brazil, France & Israel was the country of origin for five transactions in September 2021.
- 17. This data reflects U.S. targets that have been acquired by a SPAC of any nationality.
- This data reflects both U.S. and non-U.S. targets that have been acquired by a SPAC of any nationality.

The charts on p. 1–2 and 5–10 were compiled using Cortex, and are for the broader M&A market, including public and private transactions of any value. Deal volume by dollar value and average value of deals are calculated from the subset of deals that include a disclosed deal value. The charts on p. 3–4 were compiled using Deal Point Data, and include acquisitions seeking majority or higher control of U.S. targets valued at \$100 million or higher announced during the period indicated and for which a definitive merger agreement was reached and filed (except with respect to data regarding premiums and hostile/unsolicited offers, which is for all announced deals). "Last 12 Months" data is for the period from October 2020 to September 2021 inclusive. Data obtained from Cortex and Deal Point Data has not been reviewed for accuracy by Paul, Weiss.

Our Mergers & Acquisitions Practice

Paul, Weiss is a leading law firm serving the largest publicly and privately held corporations and financial institutions in the United States and throughout the world. Our firm is widely recognized for achieving an unparalleled record of success for our clients, both in their bet-the-company litigations and their most critical strategic transactions. We are keenly aware of the extraordinary challenges and opportunities facing national and global economies and are committed to serving our clients' short- and long-term goals.

The Paul, Weiss M&A Group consists of approximately 40 partners and 125 counsel and associates based in New York, Washington, Wilmington, London, San Francisco, Toronto, Tokyo, Hong Kong and Beijing. The firm's Corporate Department consists of more than 75 partners and roughly 300 counsel and associates.

Our M&A Group is among the most experienced and active in the world. We represent publicly traded and privately held companies, leading private equity firms, financial advisors, and other financial institutions and investors in their most important mergers and acquisitions, joint ventures and other strategic transactions. Our expertise advising corporations and private investors in a broad range of sophisticated transactions enables us to identify new opportunities for our clients to realize value. We have particular experience in guiding clients as they engage in proxy battles, company-altering and market consolidating transactions or capital markets transactions.

Recent highlights include advising: Qualcomm, alongside SSW Partners, in its \$4.5 billion topping bid for Veoneer; Neustar in its proposed \$3.1 billion sale, by a private investment group led by Golden Gate Capital and with minority participation from GIC, to TransUnion; Continental Grain Company in its joint venture with Cargill to acquire Sanderson Farms for a total equity value of \$4.53 billion; Translate Bio in its \$3.2 billion sale to Sanofi; Carrier Global Corporation in the proposed \$3.1 billion sale of its Chubb fire and security business to APi Group Corporation; KPS Capital Partners in its \$1.7 billion acquisition of a controlling stake in the Primary Products Business in North America and Latin America of Tate & Lyle; KPS Capital Partners and its portfolio company DexKo Global in the \$3.4 billion sale of DexKo to Brookfield Business Partners; Bowlero Corp in its proposed \$2.6 billion business combination with Isos Acquisition Corporation; the Special Committee of the Board of Directors of QAD in its proposed \$2 billion sale to Thoma Bravo; QTS Realty Trust in its \$10 billion sale to Blackstone; MGM in its proposed \$8.45 billion sale to Amazon; Advance in the \$150 billion Reverse Morris Trust transaction that will combine AT&T's WarnerMedia business with Discovery; funds managed by affiliates of Apollo Global Management in their \$5 billion acquisition of Verizon Media; Univision Holdings in its proposed \$4.8 billion combination with the content and media assets of Grupo Televisa, S.A.B.; Nuance Communications in its proposed \$19.7 billion sale to Microsoft Corp.; KPS Capital Partners in its \$2.7 billion acquisition of the EMEA food, aerosol and promotional packaging business from Crown Holding; General Electric in the more than \$30 billion combination of its jet leasing unit GE Capital Aviation Services (GECAS) with AerCap Holdings; PRA Health Sciences in its approximately \$12 billion sale to ICON; The Goodyear Tire & Rubber Company in its \$2.5 billion acquisition of Cooper Tire & Rubber Company; Perspecta Inc. in its \$7.1 billion sale to Peraton and Veritas Capital; Inspire Brands in its \$11.3 billion acquisition of Dunkin' Brands Group; Cenovus Energy in its Cdn. \$23.6 billion combination with Husky Energy; The Kraft Heinz Company in the proposed \$3.2 billion sale of its cheese business to Groupe Lactalis; an affiliate of Roark Capital Group in its approximately \$1.5 billion acquisition of the ServiceMaster Brands businesses of ServiceMaster Global Holdings; Teladoc Health in its \$18.5 billion acquisition of Livongo Health; Chevron in its \$13 billion acquisition of Noble Energy; National General Holdings in its \$4 billion sale to The Allstate Corporation; affiliates of Roark Capital in its \$200 million investment in The Cheesecake Factory; General Atlantic, as lead investor in a consortium, in its \$8.7 billion acquisition of 58.com; The Medicines Company in its \$9.7 billion sale to Novartis; the Special Committee of the Board of Directors of Pattern Energy Group in its approximately \$6.1 billion sale to Canada Pension Plan Investment Board; Aptiv in its \$4 billion autonomous driving joint venture with Hyundai Motor Group; the Special Committee of the Board of Directors of CBS Corp. in its merger with Viacom to form ViacomCBS, a combined company with an enterprise value of more than \$40 billion; Elanco Animal Health in its \$7.6 billion acquisition of the animal health business of Bayer AG; funds managed by affiliates of Apollo Global Management in their \$2.7 billion acquisition of Shutterfly; the Independent Directors of Avon in its \$3.7 billion sale to Natura & Co.; KPS Capital Partners in its \$1.8 billion acquisition of Howden from Colfax; Trane Technologies in the \$15 billion Reverse Morris Trust spin-off and merger of its industrial business with Gardner Denver Holdings; Chevron in its proposed \$50 billion acquisition of Anadarko Petroleum; General Electric in the \$21.4 billion sale of its BioPharma business to Danaher Corporation; Encana Corp. (now known as Ovintiv) in its \$7.7 billion acquisition of Newfield Exploration Company; IBM in its \$34 billion acquisition of Red Hat; the Board of Directors of Harris Corporation in its \$37 billion merger of equals with L3 Technologies to form L3Harris Technologies; CSRA in its \$9.7 billion sale to General Dynamics; Bioverativ in its \$11.6 billion sale to Sanofi; ADP in its successful proxy contest against Pershing Square; and Agrium in its \$36 billion merger of equals with Potash Corp. of Saskatchewan.

PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP

M&A at a Glance

Paul Weiss

OCTOBER 2021 | ISSUE 115

This publication is not intended to provide legal advice, and no legal or business decision should be based on its content. Questions concerning issues addressed in this memorandum should be directed to:

| Matthew W. Abbott | Scott A. Barshay | Angelo Bonvino | Ariel J. Deckelbaum |
|-------------------|------------------|-----------------|---------------------|
| +1-212-373-3402 | +1-212-373-3040 | +1-212-373-3570 | +1-212-373-3546 |
| <u>Email</u> | <u>Email</u> | <u>Email</u> | <u>Email</u> |

 Jeffrey D. Marell
 Robert B. Schumer
 Krishna Veeraraghavan
 Taurie M. Zeitzer

 +1-212-373-3105
 +1-212-373-3097
 + 1-212-373-3661
 +1-212-373-353

<u>Email</u> <u>Email</u> <u>Email</u> <u>Email</u>

Counsel Frances F. Mi, legal consultant Cara Grisin Fay, associates Andrew Forgy, Eliana Wasser and Ceecee Q. Yao, and law clerks Stephen Brady and Dylan Rogalin contributed to this publication.

Our M&A Partners

| Matthew W. Abbott | Bruce A. Gutenplan | Kenneth M. Schneider | Jeremy M. Veit |
|--------------------------|----------------------|-----------------------|--------------------|
| Edward T. Ackerman | David K. Lakhdhir | Robert B. Schumer | Michael Vogel |
| Scott A. Barshay | Brian C. Lavin | John M. Scott | Ramy J. Wahbeh |
| Angelo Bonvino | Xiaoyu Greg Liu | Brian Scrivani | Steven J. Williams |
| Ellen N. Ching | Jeffrey D. Marell | Kyle T. Seifried | Adam Wollstein |
| Ariel J. Deckelbaum | Alvaro Membrillera | Cullen L. Sinclair | Betty Yap |
| Ross A. Fieldston | Judie Ng Shortell | Sarah Stasny | Kaye N. Yoshino |
| <u>Brian P. Finnegan</u> | <u>Austin Pollet</u> | Tarun M. Stewart | Tong Yu |
| Adam M. Givertz | Carl L. Reisner | Laura C. Turano | Taurie M. Zeitzer |
| Neil Goldman | Justin Rosenberg | Krishna Veeraraghavan | |

12

^{© 2021} Paul, Weiss, Rifkind, Wharton & Garrison LLP. In some jurisdictions, this publication may be considered attorney advertising. Past representations are no guarantee of future outcomes.